|Articles|December 12, 2014

Fulvestrant as First-Line Treatment for Advanced Breast Cancer

John F. R. Robertson, MD, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

Clinical Pearls

John F. R. Robertson, MD, professor of surgery, faculty of medicine & health sciences, The University of Nottingham, United Kingdom, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

20-25 years ago, the average survival among patients with advanced breast cancer was 24 months. Now, it is 54.1 months.
Overall survival was 5.7 months higher with fulvestrant compared with anastrozole.
Benefit for fulvestrant over anastrozole was consistent across subgroups.

<<<

Go back to the SABCS conference page

Stay up to date on practice-changing data in community practice.

Fulvestrant as First-Line Treatment for Advanced Breast Cancer

Clinical Pearls

Related Content

Neoadjuvant Anbenitamab Combination Improves pCR in ERBB2+ Breast Cancer

ASCO Guideline Update Recommends Risk-Based Breast Cancer Surveillance

Gedatolisib sNDA Submitted to FDA in PIK3CA-Mutant Advanced Breast Cancer

ProSense Cryoablation Reviews Reinforce Breast Cancer De-Escalation Role

FDA Grants ETX-19477 Fast Track Designation in BRCA-Mutated Breast Cancer

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

North Carolina Oncology Association

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

Washington State Medical Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

First-Line ADC Monotherapy in mTNBC: Addressing Unmet Needs in Immunotherapy-Ineligible Populations

Combination Approaches in PD-L1–Positive mTNBC: Practice-Changing Frontline Evidence

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Building an Adequate ROS1 Workup With RNA-Based Sequencing

Switching From Chemoimmunotherapy When a ROS1 Result Returns

Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma

Ivonescimab Bests Pembrolizumab on Overall Survival in PD-L1+ NSCLC

Daraxonrasib Shows Antitumor Activity in RAS-Mutant NSCLC